CM Life Sciences II Inc. (CMIIU) News
Filter CMIIU News Items
CMIIU News Results
|Loading, please wait...
CMIIU News Highlights
- CMIIU's 30 day story count now stands at 9.
- Over the past 22 days, the trend for CMIIU's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about CMIIU are CM, MS and GRAY.
Latest CMIIU News From Around the Web
Below are the latest news stories about CM Life Sciences II Inc that investors may wish to consider to help them evaluate CMIIU as an investment opportunity.
Biotech Veterans Troy Cox, Susannah Gray and Karen McGinnis Join Biosplice Therapeutics Board of Directors
SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of three independent directors to its board. New directors comprise Troy Cox, former CEO of Foundation Medicine, Susannah Gray, former EVP and CFO of Royalty Pharma Management, and Karen McGinnis, former VP and CAO of Illumina. “We are honored to have this caliber of experience and leadership join our new board at Biosplice,” said Osman Kibar, PhD, Founder and Executive Chairman of Biosplice. “Ms. Gray, Ms. McGinnis, and Mr. Cox bring invaluable insight to our company as we continue the buildout of our alternative splicing platform and navigate the f...
CM Life Sciences II Inc. Announces Separate Trading of its Shares of Class A Common Stock and Warrants, on or about April 15, 2021
CM Life Sciences II Inc. (Nasdaq: CMIIU) (the "Company") today announced that holders of the Company’s units sold in its initial public offering may elect to separately trade the shares of Class A common stock and redeemable warrants included in its units commencing on or about April 15, 2021.
NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: Union Acquisition Corp. II (NASDAQ:LATN), Qell Acquisition Corp. (NASDAQ:QELL), CM Life Sciences II Inc. (NASDAQ:CMIIU)
BALA CYNWYD, PA / ACCESSWIRE / April 2, 2021 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions.
Graphic Source: CM Life Sciences, Inc./SomaLogic Introduction: What is CM Life Sciences II? CM Life Sciences II, Inc. (NASDAQ: CMIIU) is the second life-sciences-focused special purpose acquisition company from the Casdin-Meisters team launched in Feb 2021. CM Life Sciences II was founded to take advantage of the fragmentation of the...
Special purpose acquisition company CM Life Sciences II Inc. (CMIIU) rallied for the fourth straight session Thursday, gaining as much as 15.4% intraday as Wall Street continued to endorse its plan to buy SomaLogic at a $1.2B valuation.CMIIU rose to as high as $14.77 during the session, although it later...
SPAC CM Life Sciences (CMIIU), the SPAC backed by activist Keith Meister’s Corvex Management LP and life-sciences investor Casdin Capital, is reportedly nearing a transaction to take protein-analysis company SomaLogic Inc. public.The deal, which could be announced as soon as tomorrow, values SomaLogic at $1.25b, according to the WSJ. Investors including...
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of CM Life Sciences II Inc. (Nasdaq - CMII)
BALA CYNWYD, PA / ACCESSWIRE / March 29, 2021 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of CM Life Sciences II Inc. ("CM Life" or the "Company") (NASDAQ:CMII) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which CM Life, a special purpose acquisition company, will combine with SomaLogic, a global leader in proteomics technology, and result in SomaLogic becoming a publicly-listed company.
SomaLogic, Leading AI-Data Driven Proteomics Platform for Advanced Research and Clinical Applications, to Combine with CM Life Sciences II, to Drive Growth and Expand Technology Platform
SomaLogic, a global leader in proteomics technology, powered by a proprietary platform, the largest clinical proteomic database and next generation artificial intelligence and machine learning, and CM Life Sciences II (NASDAQ: CMIIU), a special purpose acquisition company, or SPAC, sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction CM Life Sciences II will be renamed and its common stock will be listed on the Nasdaq Global Market under ticker symbol "SLGC."